Head-To-Head Contrast: Todos Med (OTCMKTS:TOMDF) & Auna (NYSE:AUNA)

Auna (NYSE:AUNA) and Todos Med (OTCMKTS:TOMDF) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Earnings & Valuation

This table compares Auna and Todos Med”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Auna	$1.23 billion	0.32	$27.39 million	$0.36	14.68
Todos Med	N/A	N/A	N/A	N/A	N/A

Auna has higher revenue and earnings than Todos Med.

Analyst Ratings

This is a breakdown of current ratings for Auna and Todos Med, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Auna	1	1	1	2	2.80
Todos Med	0	0	0	0	0.00

Auna currently has a consensus price target of $7.30, suggesting a potential upside of 38.10%. Given Auna’s stronger consensus rating and higher probable upside, analysts plainly believe Auna is more favorable than Todos Med.

Volatility and Risk

Auna has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500. Comparatively, Todos Med has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.

Profitability

This table compares Auna and Todos Med’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Auna	2.13%	19.23%	4.70%
Todos Med	N/A	N/A	N/A

Summary

Auna beats Todos Med on 9 of the 9 factors compared between the two stocks.

About Auna

Auna S.A., a healthcare service provider, operates hospitals and clinics in Mexico, Peru, and Colombia. The company provides prepaid healthcare plans in Peru; and dental and vision plans in Mexico. The company was founded in 1989 and is based in Luxembourg, Luxembourg.

About Todos Med

Todos Medical Ltd., a vitro diagnostics company, develops and commercializes blood tests for the detection of cancer and Alzheimer disease in the United States. The company develops Total Biochemical Infrared Analysis, a proprietary cancer-screening technology using peripheral blood spectroscopy analysis for examination into cancer's influence on the immune system; Lymphocyte Proliferation Test, a diagnostic blood test that determines the ability of peripheral blood lymphocytes and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle; and blood tests for the detection of neurodegenerative disorders, such as Alzheimer's disease. Its cancer screening and diagnosis products include TM-B1 and TM-B2 for breast cancer tests; and TMC blood test for the screening and diagnosis of colon cancer. The company also offers Tollovid, a 3CL protease inhibitor dietary supplement to support healthy immune function against circulating coronaviruses; and Tollovir, an antiviral treatment for Covid-19 that is in Phase 2 clinical trial. Todos Medical Ltd. has a collaboration agreement with Integrated Health LLC, as well as has agreements with various companies to develop screening tests for SARS-nCoV-2; and to distribute certain COVID-19 test kits. Todos Medical Ltd. was incorporated in 2010 and is headquartered in Tel Aviv, Israel.